Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Capdeville

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Journal of Hepatology|September 1, 1992
Low early gallstone recurrence rate after successful extracorporeal lithotripsy in patients with solitary stonesG Pelletier, R Capdeville, H Mosnier, et al.
British Journal of Cancer|November 13, 2003
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemiaS G O'Brien, P Meinhardt, E Bond, et al.
Leukemia|October 3, 2002
Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed P-190(BCR-ABL)-positive acute lymphoblastic leukemiaG Visani, A Isidori, M Malagola, et al.
Journal of Clinical Pharmacology|March 10, 2000
Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancersH Zhou, L Choi, H Lau, et al.
The New England Journal of Medicine|April 5, 2001
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumorH Joensuu, P J Roberts, M Sarlomo-Rikala, et al.
The New England Journal of Medicine|April 5, 2001
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemiaB J Druker, M Talpaz, D J Resta, et al.
Blood|September 10, 1998
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II studyB Coiffier, C Haioun, N Ketterer, et al.
Journal of Pediatric Hematology/Oncology|July 1, 1997
Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell DiseaseM de Montalembert, M Belloy, F Bernaudin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patientsP Viens, C Chabannon, P Pouillard, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemiaP Sonneveld, A Burnett, P Vossebeld, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Journal of Hepatology|September 1, 1992
Low early gallstone recurrence rate after successful extracorporeal lithotripsy in patients with solitary stonesG Pelletier, R Capdeville, H Mosnier, et al.
British Journal of Cancer|November 13, 2003
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemiaS G O'Brien, P Meinhardt, E Bond, et al.
Leukemia|October 3, 2002
Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed P-190(BCR-ABL)-positive acute lymphoblastic leukemiaG Visani, A Isidori, M Malagola, et al.
Journal of Clinical Pharmacology|March 10, 2000
Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancersH Zhou, L Choi, H Lau, et al.
The New England Journal of Medicine|April 5, 2001
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumorH Joensuu, P J Roberts, M Sarlomo-Rikala, et al.
The New England Journal of Medicine|April 5, 2001
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemiaB J Druker, M Talpaz, D J Resta, et al.
Blood|September 10, 1998
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II studyB Coiffier, C Haioun, N Ketterer, et al.
Journal of Pediatric Hematology/Oncology|July 1, 1997
Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell DiseaseM de Montalembert, M Belloy, F Bernaudin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patientsP Viens, C Chabannon, P Pouillard, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemiaP Sonneveld, A Burnett, P Vossebeld, et al.
Pageof 5